Charles River Laboratories International (CRL) and Valo Health said Tuesday they identified their first advanceable product candidate for lupus and other autoimmune diseases using Logica.
The companies said Logica, an AI-powered drug development program born from their strategic partnership, translates biological insights into optimized preclinical assets.
The Logica Advanceable Lead program combines Valo's DNA-encoded libraries and Opal Computational Platform with Charles River's high-throughput screening to produce advanceable leads, they said.
CRL shares were 0.8% higher in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.